Compare tesamorelin vs CJC-1295 no DAC: FDA approval, half-life, dosing schedules, and side effects of these two growth hormone-releasing peptides.
Tesamorelin and CJC-1295 no DAC are both growth hormone-releasing hormone (GHRH) analogs, but they are not interchangeable. Tesamorelin is an FDA-approved prescription drug with phase 3 trial data, while CJC-1295 no DAC is an unapproved research peptide with a shorter half-life and far less human evidence. The sections below compare their chemistry, dosing, safety, and legal status.
What Each Peptide Actually Is
Tesamorelin is a synthetic 44-amino-acid GHRH analog sold under the brand name Egrifta SV. It binds GHRH receptors in the pituitary, prompting growth hormone release and a rise in IGF-1. The FDA approved it in 2010 to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
CJC-1295 no DAC is a shorter 29-amino-acid analog, often written as mod GRF (1-29). It was designed to resist enzymatic breakdown while producing a brief, natural-looking growth hormone pulse. "No DAC" means it does not carry the Drug Affinity Complex that gives CJC-1295 with DAC its week-long activity.
Both compounds work through the same receptor, so they are better understood as different delivery strategies for the same hormone pathway than as unrelated drugs.
Tesamorelin vs CJC-1295 No DAC at a Glance
The largest difference between these two compounds is regulatory rather than chemical. Tesamorelin is an approved medicine for a specific diagnosis; CJC-1295 no DAC is sold only as a research chemical.
| Feature | Tesamorelin | CJC-1295 No DAC |
|---|---|---|
| Also known as | Egrifta SV, TH9507 | Mod GRF (1-29) |
| FDA status | Approved for HIV-associated lipodystrophy | Not approved for human use |
| Half-life | About 26-38 minutes | About 30 minutes |
| Typical dose | 2 mg once daily (labeled use) | 100 mcg, 2-3 times daily (research only) |
| Route | Subcutaneous injection | Subcutaneous injection |
| Human trial data | Extensive, including phase 3 | Minimal |
Half-Life and Dosing Differences
Tesamorelin clears the body in roughly half an hour, which supports a single 2 mg subcutaneous injection per day in its approved indication. CJC-1295 no DAC is similarly short-lived, so research protocols usually split it into smaller, more frequent doses instead of one large shot.
In research settings, the cjc-1295 no dac dosage most often described is 100 mcg per injection, given two or three times daily. That schedule is intended to mimic the body's pulsatile growth hormone release. Because the peptide degrades quickly, timing appears to matter more than total weekly amount.
The question of cjc-1295 dac vs no dac which is better comes down to the shape of the growth hormone pulse you want. The DAC version stays active for 6 to 8 days and creates sustained elevation, while the no DAC version produces a short spike that some researchers consider more physiological.
Clinical Evidence and Reported Effects
Tesamorelin has the stronger evidence base by a wide margin. In phase 3 trials of adults with HIV-associated lipodystrophy, 2 mg daily reduced visceral adipose tissue by roughly 15 to 18 percent over 26 weeks and raised IGF-1 levels.
CJC-1295 no DAC has no comparable human trials. Most available information comes from user reports, which is one reason cjc 1295 no dac ipamorelin reddit threads should be read as personal anecdotes rather than clinical evidence. Anecdotal reports frequently describe improved sleep, appetite, and recovery, but none of these outcomes have been confirmed in controlled studies.
Side Effects, Safety, and Common Stacks
Both peptides raise growth hormone and IGF-1, so both carry the theoretical risks of that pathway. Reported effects with GHRH analogs include:
- Injection-site redness, pain, or nodules
- Joint aches and stiffness
- Fluid retention and swelling in the hands or feet
- Carpal tunnel-like numbness or tingling
- Changes in blood sugar and insulin sensitivity
Persistently elevated IGF-1 is a concern with any GHRH analog, and long-term supraphysiologic exposure has not been well studied in healthy adults. Blood work monitoring is generally recommended for anyone using these compounds under medical supervision.
People comparing cjc-1295 ipamorelin vs tesamorelin are usually weighing a two-peptide stack against a single approved drug. CJC-1295 no DAC is often paired with ipamorelin because the two act on different receptors and are thought to amplify the growth hormone pulse.
Another frequent comparison is cjc-1295 no dac vs sermorelin, since sermorelin is also a GHRH analog with a longer clinical history and a very short half-life. Anyone weighing tesamorelin vs sermorelin vs cjc-1295 should note that sermorelin's branded product was discontinued years ago, while tesamorelin remains the only GHRH analog with an active FDA approval for human use.
Legal Status and the Bottom Line
CJC-1295 no DAC is not FDA-approved for human use in the United States. Products sold online are labeled "for research use only" and are not held to the purity, sterility, and potency standards required of prescription drugs.
Tesamorelin is available only by prescription and only for its labeled indication. Using it for body composition or anti-aging purposes is off-label and should involve a licensed healthcare professional who can monitor IGF-1, blood glucose, and injection-site reactions.
The bottom line: tesamorelin is a regulated medicine with proven effects on visceral fat in a specific patient population, and CJC-1295 no DAC is an unapproved research peptide with limited human data. Neither should be used without medical guidance, and neither is a substitute for the other in a research or clinical setting.
Frequently Asked Questions
Is tesamorelin the same as CJC-1295 no DAC?
No. Tesamorelin is a 44-amino-acid GHRH analog approved by the FDA as Egrifta SV, while CJC-1295 no DAC is a 29-amino-acid research peptide that is not approved for human use. They act on the same receptor but differ in half-life, dosing frequency, and legal status.
Can you stack tesamorelin with CJC-1295 no DAC?
Stacking them is not supported by clinical research, because both work through the GHRH receptor and combining them may add side effects without adding benefit. Anyone considering a GHRH analog stack should discuss it with a healthcare professional first.
What is the typical CJC-1295 no DAC dosage?
Research protocols commonly describe 100 mcg per subcutaneous injection, two to three times daily, because the peptide's half-life is only about 30 minutes. No FDA-approved dosing exists for humans, and self-dosing carries unknown risks.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.